This article is more than 5 years old. Information may no longer be current.
Close follow-up recommended for posterior ischemic ROP treated with anti-VEGF
 Amin Kherani |
BOSTON — Regression patterns for posterior ischemic retinopathy of prematurity after treatment with bevacizumab suggest close follow-up beyond 60 weeks post-conception, according to a study here.
Amin Kherani, MD, presented the retrospective analysis at the American Society of Retina Specialists meeting. Sixty eyes of 30 premature infants with aggressive ROP stage 3 plus zone 1 or zone 2 posterior were evaluated within or outside of the BEAT-ROP study.
Patients received 0.625 mg of Avastin (bevacizumab, Genentech) as first-line therapy, and at 60 to 70 weeks post-conception, 73% had vascularized to within 2 disc diameters of the ora serrata.
Of the remaining 27%, two eyes had resistance, two had early recurrence, four had silent brush border, four had leakage, two developed macular dragging and two experienced retinal detachment.
"The take-home message is it obligates us to follow these patients closely and address these issues early rather than late," Dr. Kherani said.
- Disclosure: Dr. Kherani has no relevant financial disclosures.